3 Thyroid Markers Your Doctor Is Missing | Dr. Amie Hornamen
Why It Matters
Recognizing and treating reverse T3 elevation enables personalized thyroid therapy, reducing misdiagnosis and improving health outcomes for millions, especially menopausal women.
Key Takeaways
- •Reverse T3 testing reveals excess T4 and hidden hypothyroidism.
- •Standard TSH‑only protocols miss conversion issues and genetic variants.
- •Menopausal women often experience undiagnosed thyroid dysfunction and symptom overlap.
- •Nutrient deficiencies, stress, and insulin resistance impede T4‑to‑T3 conversion.
- •Personalized T3‑only therapy can restore energy and metabolic health.
Summary
The video spotlights three thyroid markers—TSH, free T3, and reverse T3—that many clinicians overlook, especially in women navigating perimenopause and menopause. Dr. Amie Hornamen argues that standard allopathic practice relies solely on TSH and T4 monotherapy, assuming every patient will adequately convert T4 to active T3, a premise that often fails. Key insights include the role of reverse T3 as a survival‑mode hormone that rises when excess T4 is present or conversion pathways are blocked. Genetic polymorphisms (DIO1/DIO2), estrogen dominance, insulin resistance, and nutrient shortfalls such as iodine, selenium, and magnesium can all divert T4 toward reverse T3, leaving patients fatigued, foggy, and resistant to weight‑loss interventions. Hornamen shares personal anecdotes—her own turnaround after starting thyroid replacement—and cites epidemiological data suggesting that while one‑in‑eight Americans are diagnosed with hypothyroidism, the true prevalence may approach one‑in‑four due to misdiagnosis and gaslighting. She also references a patient whose high reverse T3 persisted despite correcting deficiencies, underscoring the need for comprehensive testing. The implications are clear: clinicians should expand lab panels to include reverse T3 and free T3, consider T3‑only or combined therapy for select patients, and address underlying metabolic stressors. Doing so can improve patient outcomes, enhance the efficacy of adjunct treatments like GLP‑1 agonists, and open new revenue streams for practices embracing functional‑medicine protocols.
Comments
Want to join the conversation?
Loading comments...